ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← November 13, 2026 edited reader edition

THE ARISING · Science & Frontiers

The FDA Asks Gene Therapy Makers to Show Potency Across Batches

Final guidance makes the distinction clear: a consistent product is necessary, but it does not prove that a treatment will help patients.

When a cell or gene therapy looks promising in a study, the next patient needs more than a report on the first patients’ results. The developer also has to show that a new batch is capable of the intended biological activity. In November 2026, the FDA issued final guidance on how manufacturers should approach that question.

The guidance replaces the agency’s 2011 document on potency testing for cell and gene therapy products. It recommends a strategy for building confidence in potency throughout a product’s development and manufacture, rather than relying on a single test at the end. The FDA describes the strategy as flexible and grounded in the risks of the particular product. This is guidance for manufacturers, not a new approval or a blanket rule that all therapies must use the same test.

Potency and clinical benefit answer different questions. Potency is about a product’s capacity to perform its intended biological activity. A clinical trial asks whether that activity, in actual patients, produces a meaningful improvement with acceptable harms. Regulators and clinicians need both kinds of evidence. A credible potency result does not show that the treatment works for a particular disease, that its effects will last or that it is safe.

The 8th Cell & Gene Therapy Analytical Development Summit was scheduled for Dec. 1–3 in Boston. Its focus on measurement underscores the industry’s attention to this problem, but a commercial meeting agenda does not establish a finding or endorse a therapy.

For readers following new treatments, the useful questions are separate: did patients benefit in a credible trial, and can the manufacturer show that later batches remain comparable? The FDA guidance is about the second question. It should not be read as an answer to the first.

FDA’s final potency assurance guidance

FDA’s Nov. 2 announcement

Conference organizer’s date and program information

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗